Roche's antibody-drug conjugate Kadcyla looks well positioned for approval for adjuvant treatment of breast cancer, following the release of positive top-line findings from the KATHERINE study on Oct. 15.
Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer
KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of breast cancer.
